|
2024 Conference Publication A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309 |
|
2023 Conference Publication Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND TrialRoberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2022 Conference Publication Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final resultsPavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC)Pathmanathan, Shivanshan, Tariq, Arsalan, Gan, Chun Loo, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Philip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C. and Roberts, Matthew (2022). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, 3-7 June 2022. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2022.40.16_suppl.4540 |
|
2021 Conference Publication 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer CenterNalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198 |
|
2019 Conference Publication Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]Sandhu, Shahneen, Tothill, Richard, Scolyer, Richard, Guminski, Alexander, Becker, Juergen, Poulsen, Michael, Atkinson, Victoria, Neeson, Paul, Shackleton, Mark, Pattison, David, Williams, Narelle and Paton, Elizabeth (2019). Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Hoboken, NJ, United States: Wiley. |
|
2019 Conference Publication A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerDebowski, M., Gulhane, B., Ramsay, S. C., Thomas, P. A., Garcia, P., Latter, M., Tapper, S. and Pattison, D. A. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 49th ASM, Adelaide, SA, Australia, 26–28 April 2019. Hoboken, NJ, United States: Wiley. |
|
2018 Conference Publication Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)Scott, Ashleigh P., Tey, Siok-Keen, Thomas, Paul, Pattison, David and Kennedy, Glen A. (2018). Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114114 |
|
2018 Conference Publication (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKERobinson, B., Pattison, D. and Lee, K. (2018). (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE. HOBOKEN: WILEY. |
|
2018 Conference Publication Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumorLadwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECTGoodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018. |
|
2018 Conference Publication Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumorsLadwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2017 Conference Publication 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL)Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M. S., Meirovitz, A., Maimon, O., Pattison, D. A., Gross, D. J. and Hicks, R. J. (2017). 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL). HOBOKEN: WILEY. |
|
2017 Conference Publication USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVALMacFarlane, L. and Pattison, D. (2017). USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVAL. HOBOKEN: WILEY. |
|
2017 Conference Publication The management of refractory catecholamine associated symptoms in malignant phaeochromocytomaMossman, Anna, Pattison, David, Inchley, Fiona and Hamblin, P. Shane (2017). The management of refractory catecholamine associated symptoms in malignant phaeochromocytoma. HOBOKEN: WILEY-BLACKWELL. |
|
2017 Conference Publication Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M., Meirovitz, A., Maimon, O., Pattison, D., Gross, D. and Hicks, R. (2017). Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL). 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 08-10, 2017. BASEL: KARGER. |
|
2016 Conference Publication PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)Pattison, D., Kong, G., Messazos, B., Hamblin, P., Fourlanos, S., Lee, M., Michael, M., Hong, E., Eu, P. and Hicks, R. (2016). PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS). HOBOKEN: WILEY-BLACKWELL. |
